Table 2.
Expression of VEGF, VEGFR2, Ki-67, Glut-1, p-AKT and p-ERK in human hemangiomas.
| Target | Group | Cases | n | Positive rate (%) | X2 | P | |||
|---|---|---|---|---|---|---|---|---|---|
| - | + | ++ | +++ | ||||||
| VEGF | Proliferating phase HAs | 30 | 6 | 7 | 12 | 5 | 80.0 | 11.712 | 0.001 |
| Involuting phase HAs | 25 | 13 | 9 | 3 | 0 | 48.0 | |||
| VEGFR2 | Proliferating phase HAs | 30 | 8 | 6 | 10 | 6 | 73.3 | 8.628 | 0.003 |
| Involuting phase HAs | 25 | 15 | 6 | 3 | 1 | 40.0 | |||
| Ki-67 | Proliferating phase HAs | 30 | 7 | 12 | 6 | 5 | 76.7 | 5.559 | 0.018 |
| Involuting phase HAs | 25 | 14 | 6 | 4 | 1 | 44.0 | |||
| Glut-1 | Proliferating phase HAs | 30 | 5 | 8 | 8 | 9 | 83.3 | 19.921 | <0.001 |
| Involuting phase HAs | 25 | 18 | 5 | 2 | 0 | 28.0 | |||
| p-AKT | Proliferating phase HAs | 30 | 8 | 13 | 7 | 2 | 73.3 | 8.512 | 0.004 |
| Involuting phase HAs | 25 | 16 | 7 | 2 | 0 | 36.0 | |||
| p-ERK | Proliferating phase HAs | 30 | 10 | 13 | 5 | 2 | 66.7 | 8.913 | 0.003 |
| Involuting phase HAs | 25 | 18 | 6 | 1 | 0 | 28.0 | |||
Has, hemangiomas.